Home  »  Companies   »  Praxis Precision Medicines Inc. (NASDAQ: PRAX) Fel...

Praxis Precision Medicines Inc. (NASDAQ: PRAX) Fell -9.65%, Now What? Don’t Panic

Praxis Precision Medicines Inc. (NASDAQ:PRAX) price on Friday, March 17, fall -9.65% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.03.

A look at the stock’s price movement, the close in the last trading session was $1.14, moving within a range at $1.025 and $1.15. The beta value (5-Year monthly) was 3.14. Turning to its 52-week performance, $13.33 and $0.98 were the 52-week high and 52-week low respectively. Overall, PRAX moved -72.16% over the past month.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Praxis Precision Medicines Inc.’s market cap currently stands at around $52.96 million, with investors looking forward to this quarter’s earnings report slated for May 08, 2023 – May 12, 2023. Analysts project the company’s earnings per share (EPS) to be -$0.78, which has seen fiscal year 2023 EPS growth forecast to increase to -$2.87 and about -$2.77 for fiscal year 2024. Per the data, EPS growth is expected to be 38.10% for 2023 and 3.50% for the next financial year.

Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was 1 upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that PRAX is a 100% Sell. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.

PRAX’s current price about -53.04% and -68.19% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 19.33, while 7-day volatility ratio is 8.05% and 10.43% in the 30-day chart. Further, Praxis Precision Medicines Inc. (PRAX) has a beta value of 0, and an average true range (ATR) of 0.24.

In the market, a comparison of Praxis Precision Medicines Inc. (PRAX) and its peers suggest the former has performed considerably weaker. Data shows PRAX’s intraday price has changed -9.65% in last session and -90.35% over the past year. Comparatively, Moderna Inc. (MRNA) has moved -1.16% on the day and only -11.42% in the past 12 months. Moreover, Jazz Pharmaceuticals plc (JAZZ) is also down -1.52% in trading on the day while keeping a a downtrend of -14.65% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -1.10% and -1.19% respectively in the last trading.

If we refocus on Praxis Precision Medicines Inc. (NASDAQ:PRAX), historical trading data shows that trading volumes averaged 2.99 million over the past 10 days and 1.99 million over the past 3 months. The company’s latest data on shares outstanding shows there are 47.61 million shares.

The 0.60% of Praxis Precision Medicines Inc.’s shares are in the hands of company insiders while institutional holders own 90.30% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.14 million on Jan 12, 2023, giving us a short ratio of 1.58. The data shows that as of Jan 12, 2023 short interest in Praxis Precision Medicines Inc. (PRAX) stood at 4.54% of shares outstanding, with shares short rising to 1.91 million registered in Dec 14, 2022. Current price change has pushed the stock -56.72% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PRAX stock continues to rise going into the next quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *